Detailed price information for Royalty Pharma Plc Cl A (RPRX-Q) from The Globe and Mail including charting and trades.

Detailed price information for Royalty Pharma Plc Cl A (RPRX-Q) from The Globe and Mail including charting and trades.

Cycurion Inc.  ("Cycurion" or the "Company") today announced that it plans to distribute a special dividend valued at $500,000 in the form of its CYCU common shares to all of its shareholders of ...

Discover how the Impact of R&D on Biotech Companies in India is driving innovation, boosting exports and transforming pharma, ...

Spatial RNA medicine combines transcriptomics and RNA therapeutics, mapping gene expression in tissues to enhance precision ...

Below, CNBC Select explains the differences between trademarks, copyrights and patents. Read on for more information and to ...

The last two decades have not been kind to science studies. Already bruised and battered by the “science wars” of the 1990s, ...

Denali Therapeutics Inc. (Nasdaq: DNLI) and Royalty Pharma plc (Nasdaq: RPRX) today announced a $275 million synthetic royalty ...

Utilizing its innovative ADC payload platform, Akari is advancing a new class of immuno-oncology ADCs built on the platform of a novel PH1 payload. This payload is designed specifically to target and ...

APONVIE, an aprepitant product, highlighted as the only FDA-approved IV formulation Neurokinin-1 ('NK-1”) antagonist ...

For super-resolution microscopes, AI helps by restoring images from even noisy, low-fluorescence data. That capability helps ...

Despite the importance of GoF modifications, they have sometimes faced misplaced concerns or opposition that could lead to their being overregulated or even banned.